Since ovarian cancers with mutations in BRCA1 or BRCA2 are more sensitive to platinum-containing chemotherapy, we asked whether the total number of somatic mutations in ovarian cancer predicts sensitivity to chemotherapy and clinical outcome. This evidence concerns the gene BRCA1 and ovarian cancer.